1-4 of 4
Jesse McGreivy, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jennifer R. Brown, MD PhD, Peter Hillmen, MB, ChB, PhD, Susan O'Brien, MD, Jaqueline C. Barrientos, MD, Nishitha Reddy, MBBS, MScl, Steven Coutre, MD, Constantine Tam, MD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Ulrich Jaeger, MD, Paul M. Barr, MD, Richard R. Furman, MD, Thomas J. Kipps, MD, Florence Cymbalista, MD, Patrick Thornton, MD, Federico Caligaris-Cappio, MD, Julio Delgado, MD, Marco Montillo, MD, Sven DeVos, MD, Carol Moreno, MD, John Pagel, MD PhD, Jan A. Burger, MD PhD, Devon Chung, BS, Jennifer Lin, MA, MS, Linda Gau, MS, Betty Chang, PhD, Jesse McGreivy, MD, Danelle F. James, MD MAS, John C. Byrd, MD
Journal: Blood
Blood (2014) 124 (21): 3331.
https://doi.org/10.1182/blood.V124.21.3331.3331
Published: 2014
Journal Articles

The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma

Nathan H Fowler, MD, Ranjana H Advani, MD, Jeff Sharman, MD, Sonali M. Smith, MD, Jesse McGreivy, MD, Lori Kunkel, MD, Vina Troung, Cathy Zhou, Thomas E. Boyd, MD
Journal: Blood
Blood (2012) 120 (21): 156.
https://doi.org/10.1182/blood.V120.21.156.156
Published: 2012
Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study

Wyndham H. Wilson, MD, PhD, John F. Gerecitano, MD, PhD, Andre Goy, MD, Sven de Vos, MD, PhD, Vaishalee P. Kenkre, MD, Paul M. Barr, MD, Kristie A. Blum, MD, Andrei R. Shustov, MD, Ranjana H. Advani, MD, Jason Lih, PhD, Mickey Williams, PhD, Roland Schmitz, PhD, Yandan Yang, PhD, Stefania Pittaluga, MD, PhD, George Wright, PhD, Lori A. Kunkel, MD, Jesse McGreivy, MD, Sriram Balasubramanian, PhD, Mei Cheng, PhD, Davina Moussa, Joseph J. Buggy, PhD, Louis M. Staudt, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 686.
https://doi.org/10.1182/blood.V120.21.686.686
Published: 2012
Journal Articles

Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up

Michael Wang, M.D., Simon A. Rule, MD, Peter Martin, MD, Andre Goy, MD, Rebecca Auer, MD, Brad S. Kahl, M.D., Wojciech Jurczak, Ranjana H. Advani, MD, Jorge Enrique E Romaguera, MD, Jesse McGreivy, MD, Fong Clow, ScD, Michelle Stevens-Brogan, Lori Kunkel, MD, Kristie A. Blum, MD
Journal: Blood
Blood (2012) 120 (21): 904.
https://doi.org/10.1182/blood.V120.21.904.904
Published: 2012